Dana dhuwit saben siji saham cellectis.com (CLLS)

Simbol lan logo merek Cellectis (CLLS)

Geopolitical risks and the fragmentation of data laws are forcing Cellectis S.A. (CLLS) to rely on a powerful alliance with AstraZeneca and TALEN technologies, which is confirmed by the cash position per share chart. The value of 2.32 determines the current status of the liquidity parameter. Completing the picture is the company's status as a pioneer of allogeneic CAR-T systems, which make express therapy accessible to a wide range of patients.

CLLS cellectis.com: Dhuwit awis saben siji saham ing interval 04.07.2022 - 20.11.2026

Rincian metrik komprehensif lan analitis cellectis.com (CLLS)

- rega pasar lan target rega analis:
- data dhuwit lan arus kas:
Ringkesan analisis perusahaan:CLLS (Cellectis SA)
Produk dadi Cellectis S.A.

Outsourcing vector production and testing allows Cellectis S.A. (CLLS) to optimize expenses by focusing on gene editing. Current fluctuations in cash per share at 2.32 reflect the business's real-time liquid reserve per share without reporting delays, which determines the company's financial autonomy and its ability to sustain development during periods of market volatility.